Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Proliferative Diabetic Retinopathy
Conditions
Non-Proliferative Diabetic Retinopathy
Trial Timeline
Nov 17, 2025 → Mar 1, 2027
NCT ID
NCT07235085About Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 is a phase 3 stage product being developed by Ocular Therapeutix for Non-Proliferative Diabetic Retinopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07235085. Target conditions include Non-Proliferative Diabetic Retinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07235085 | Phase 3 | Recruiting |
Competing Products
2 competing products in Non-Proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OTX-TKI + Sham | Ocular Therapeutix | Phase 1 | 28 |
| KSI-301 | Kodiak Sciences | Phase 3 | 72 |
Other Products from Ocular Therapeutix
Dextenza + Prednisolone AcetateApproved
80
Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal PulsationApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone AcetateApproved
80
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%Approved
80
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Approved
80